BioStem Technologies宣布根据纳斯达克规则以市价定价完成300万美元的私募配售-动脉网

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire 等信源发布 2026-09-30 12:00



可切换为仅中文







POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company’s common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock, at a purchase price of $4.08 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules.

佛罗里达州庞帕诺比奇，2026年9月30日（环球电讯社）——领先再生医学公司BioStem Technologies Inc.（纳斯达克股票代码：BSEM）（以下简称“BioStem”或“公司”），专注于围产期组织同种异体移植产品的开发、制造和商业化，今日宣布已签订最终协议，以每股4.08美元的价格，在根据纳斯达克规则按市场定价的私募配售中，发行并出售735,296股公司普通股、最多可购买总计735,296股普通股的A系列认股权证，以及最多可购买总计735,296股普通股的B系列认股权证。

The warrants will have an exercise price of $3.83 per share and will be exercisable immediately upon issuance. The Series A warrants will expire five years after the effective date of the Resale Registration Statement (as defined below) and the Series B warrants will expire twenty-four months after the effective date of the Resale Registration Statement..

认股权证的行权价格为每股3.83美元，并将在发行后立即可行使。A系列认股权证将在转售注册声明（定义见下文）生效日起五年后到期，B系列认股权证将在转售注册声明生效日起二十四个月后到期。

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

H.C. Wainwright & Co. 担任本次发行的独家配售代理。

The aggregate gross proceeds to the Company from the offering are expected to be approximately $3 million, before deducting placement agent fees and other offering expenses. If the Series A and Series B warrants are exercised in full for cash, the Company would receive additional gross proceeds of approximately $5.6 million.

在扣除配售代理费用及其他发行费用之前，公司从本次发行中获得的总收益预计约为300万美元。如果A系列和B系列认股权证被全额现金行权，公司将额外获得约560万美元的总收益。

There can be no assurance that any of the warrants will be exercised. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes..

无法保证任何认股权证将被行权。预计本次发行将于2026年9月30日或左右完成，但须满足惯常的交割条件。公司拟将本次发行的净收益用于营运资金及一般公司用途。

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Act or applicable state securities laws.

上述证券正根据经修订的《1933年证券法》（以下简称“《法案》”）第4(a)(2)条及其下颁布的D条例以私募方式发售，且该等证券以及本次发售中出售的认股权证所对应的普通股股份均未根据《法案》或适用的州证券法进行注册。

Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock to be issued in the offering and issuable upon exercise of the warrants to be issued in the offering (the “Resale Registration Statement”)..

因此，在未向美国证券交易委员会（SEC）注册或适用该等注册要求的豁免的情况下，不得在美国要约出售或销售此类证券。根据一项注册权协议，公司已同意向美国证券交易委员会提交一份或多份注册声明，涵盖在本次发行中将发行的普通股股份以及因行使在本次发行中将发行的认股权证而可发行的普通股股份的转售事宜（下称“转售注册声明”）。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或购买这些证券的要约邀请，也不得在任何州或司法管辖区进行这些证券的销售，如果在该等州或司法管辖区内，此类要约、邀请或销售在根据该州或司法管辖区的证券法进行注册或资格认定之前是非法的。

About BioStem Technologies, Inc.

关于 BioStem Technologies, Inc.

(Nasdaq: BSEM):

（纳斯达克股票代码：BSEM）：

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings.

BioStem Technologies, Inc. 是一家公开上市的生物医学创新企业，专注于开发、制造和商业化源自围产期组织的先进同种异体移植物解决方案。公司凭借其行业领先的专有 BioRetain®、CryoTek® 和 SteriTek® 加工技术，旨在优化这些组织天然特性的保存，从而支持其在临床环境中的应用。

Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine..

其同种异体移植物被广泛应用于各个专科领域的临床医生。凭借日益丰富的产品组合、不断扩展的临床研究项目以及覆盖全国的商业布局，BioStem 致力于推动再生医学领域的创新。

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”).

BioStem Technologies 的质量管理体系和标准操作规程已接受美国组织库协会（“AATB”）的审查并获得认证。这些体系和程序的建立符合现行良好组织规范（“cGTP”）和现行良好生产规范（“cGMP”）。

BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines..

BioStem 的优质品牌组合包括其 Neox®、Clarix®、VENDAJE® 和 American Amnion™ 产品线。

Forward-Looking Statements:

前瞻性声明：

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

本新闻稿中的某些陈述可能被视为1995年《私人证券诉讼改革法》意义上的“前瞻性陈述”。这些前瞻性陈述涉及对未来事件的预期或预测。前瞻性陈述可通过使用“预测”、“打算”、“寻求”、“目标”、“预期”、“相信”、“期望”、“估计”、“计划”、“展望”和“规划”等词语以及其他类似表述来识别，这些词语或表述用于预测或指示未来事件或趋势，而非对历史事实的陈述。

Forward-looking statements in this press release include, without limitation, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the potential exercise of the warrants and the intended use of net proceeds from the offering..

本新闻稿中的前瞻性陈述包括但不限于，有关完成此次发行、满足与此次发行相关的惯例交割条件、潜在行使认股权证以及拟使用此次发行所得净收益的陈述。

Forward-looking statements with respect to strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements.

有关本公司战略、前景及业务其他方面的前瞻性陈述均基于当前预期，而这些预期受已知和未知风险与不确定性的影响，可能导致实际结果或 outcome 与此类前瞻性陈述所明示或暗示的预期存在重大差异。

These factors include, but are not limited to: the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; the Company’s ability to obtain financing on terms acceptable to it, or at all; the impact of any changes in applicable laws or regulations; the Company's accounts receivable collection risk and concentration; the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and the possibility that the Company may be adversely affected by other general economic, business, and/or competitive factors.

这些因素包括但不限于：公司维持符合纳斯达克持续上市标准的能力；公司以可接受条款或根本无法获得融资的能力；任何适用法律或法规变更的影响；公司应收账款的回收风险及集中度；公司维持足够产品产量以满足需求的能力；以及公司可能受到其他总体经济、商业和/或竞争因素不利影响的可能性。

There may be additional risks about which the Company is presently unaware of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

可能存在公司目前尚未知晓或公司当前认为不重大的其他风险，这些风险也可能导致实际结果与前瞻性陈述中所载的内容存在差异。谨提醒您不要过度依赖任何前瞻性陈述，这些陈述仅反映其作出之日的情况。

The Company undertakes no duty to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law..

除法律另有要求外，本公司不承担因新信息、未来事件或其他原因而更新或修订前瞻性陈述的义务。

Join BioStem’s Distribution List & Social Media:

加入 BioStem 的邮件分发列表及社交媒体：

To follow the latest developments at BioStem, sign up for the Company’s email distribution list

如需了解 BioStem 的最新动态，请注册加入公司的电子邮件分发列表

HERE

这里

, and follow us on

，并在上关注我们

and

和

领英